The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer.
Abstract
Neuronatin (NNAT) determined by immunohistochemistry is a negative prognostic biomarker for breast cancer, independent of the major clinicopathological markers. Here, we investigated whether NNAT is also a predictive biomarker for pathological remission after neoadjuvant chemotherapy. One hundred and four breast cancer patients, treated with systemic neoadjuvant chemotherapy were included in this retrospective study. NNAT was detected in formaldehyde fixed, paraffin embedded primary cancer tissue by immunohistochemistry and an immuno-reactive score (IRS) determined. Pathological remission was scored according to Sinn and by evaluation of cytopathic effects. NNAT-IRS was correlated with clinicopathological parameters as well as relapse free and overall survival and for pathological remission after neoadjuvant therapy. NNAT IRS was an independent prognostic marker for relapse free and overall survival and the time from diagnosis to the "tumor-free" state. NNAT IRS was associated with Luminal-A tumors and correlated slightly negative with age and lymph-node metastasis. There was no significant correlation of NNAT-IRS with Sinn's remission score, but with cytopathic effects of chemotherapy. We confirmed the prognostic impact of NNA...Continue Reading
References
Neuronatin expression and its clinicopathological significance in pulmonary non-small cell carcinoma
Related Concepts
Related Feeds
Cancer Vaccines
Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.